Qiagen N.V. Common Shares (NY:QGEN)

50.39 +0.17 (+0.34%)

Official Closing Price Updated: 4:10 PM EDT, Oct 23, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Qiagen N.V. Common Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

QIAGEN N.V. (NYSE:QGEN) Passes the Caviar Cruise Quality Investment Screen ↗

October 18, 2025

QIAGEN NV exemplifies the Caviar Cruise investing method with strong sales growth, a 46% ROIC, and robust cash flow, signaling a high-quality business.

Via Chartmill

QIAGEN N.V. to Release Results for Q3 2025 and Hold Webcast

October 13, 2025

From QIAGEN N.V.

Via Business Wire

Illumina's BioInsight Launch Sparks Optimism, Signals New Era for Genomic Data and AI

October 01, 2025

San Diego, CA – October 1, 2025 – Illumina, Inc. (NASDAQ: ILMN) saw its shares surge by 6.6% today following the announcement and immediate launch of its new business unit, BioInsight. This strategic...

Via MarketMinute

Topics Artificial Intelligence Intellectual Property

Earnings Scheduled For August 5, 2025 ↗

August 05, 2025

Via Benzinga

A Look at Qiagen's Upcoming Earnings Report ↗

August 04, 2025

Via Benzinga

Earnings Scheduled For May 7, 2025 ↗

May 07, 2025

Via Benzinga

Earnings Scheduled For November 4, 2025 ↗

November 04, 2025

Via Benzinga

QIAGEN Launches New Automated Sexual Assault Sample Processing Kit at ISHI 2025

October 30, 2025

From QIAGEN N.V.

Via Business Wire

QIAGEN Marks 4,000th QIAcube Connect Placement, Reaffirming Leadership in Automated Sample Processing

October 28, 2025

From QIAGEN N.V.

Via Business Wire

QIAGEN Secures European CE-IVDR Certification for Full QIAstat-Dx Portfolio

September 10, 2025

From QIAGEN N.V.

Via Business Wire

QIAGEN Gains U.S. Clearance of Higher-Throughput QIAstat-Dx Rise, Expanding Patient Access to Rapid Syndromic Testing

September 02, 2025

From QIAGEN N.V.

Via Business Wire

DoorDash To Rally Around 30%? Here Are 10 Top Analyst Forecasts For Thursday ↗

August 07, 2025

Via Benzinga

QIAGEN exceeds outlook for Q2 2025 with solid growth and improved profitability

August 05, 2025

From QIAGEN N.V.

Via Business Wire

QIAGEN Expands NGS Portfolio with Launch of QIAseq xHYB Long Read Panels

July 22, 2025

From QIAGEN N.V.

Via Business Wire

QIAGEN N.V. (NYSE:QGEN) - A Strong Technical Setup for Breakout Investors ↗

July 21, 2025

QIAGEN N.V. (NYSE:QGEN) shows strong technicals and a high-quality breakout setup, making it a candidate for momentum traders. The stock trades near 52-week highs with clear support and resistance...

Via Chartmill

QIAGEN N.V. to Release Results for Q2 2025 and Hold Webcast

July 08, 2025

From QIAGEN N.V.

Via Business Wire

QIAGEN Announces Election of Stephen Rusckowski as Chairman of Supervisory Board

June 26, 2025

From QIAGEN N.V..

Via Business Wire

QIAGEN N.V. (NYSE:QGEN) – A Quality Stock Worth Considering ↗

June 26, 2025

QIAGEN N.V. (NYSE:QGEN) is a quality stock with strong revenue growth, high ROIC, and solid cash flow conversion, making it a candidate for long-term investors.

Via Chartmill

QIAGEN and GENCURIX Announce QIAcuity Digital PCR IVD Assay Development Partnership

June 18, 2025

From QIAGEN N.V.

Via Business Wire

Retail Investors Flock To Incyte As Drug Data, Qiagen Deal Fuel Optimism ↗

June 16, 2025

Stifel also upgraded the stock to ‘Buy’ with a $107 price target.

Via Stocktwits

QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)

June 15, 2025

From QIAGEN N.V.

Via Business Wire

QIAGEN expands portfolio for minimal residual disease (MRD) testing in oncology with new strategic partnerships

June 02, 2025

From QIAGEN N.V.

Via Business Wire

QIAGEN N.V. (NYSE:QGEN) – A Quality Stock with Strong Fundamentals ↗

June 02, 2025

QIAGEN N.V. (NYSE:QGEN) is a quality stock with strong revenue growth, high ROIC, and solid financial health, making it a candidate for long-term investors.

Via Chartmill

QIAGEN expands digital PCR oncology research portfolio through partnership with ID Solutions

May 22, 2025

From QIAGEN N.V.

Via Business Wire

QIAGEN enhances leading clinical genomics portfolio with acquisition of Genoox AI-powered software

May 12, 2025

From QIAGEN N.V.

Via Business Wire

QIAGEN announces plans for transition in leadership of Supervisory Board

May 07, 2025

From QIAGEN N.V.

Via Business Wire

QIAGEN delivers solid Q1 2025 results exceeding outlook; will seek shareholder approval to initiate a dividend and new $500 mn repurchase

May 07, 2025

From QIAGEN N.V.

Via Business Wire

QIAGEN to Propose Initiation of Annual Cash Dividend for Shareholder Approval at Annual General Meeting

May 07, 2025

From QIAGEN N.V.

Via Business Wire

QIAGEN Expands Its Digital PCR Portfolio With New Lentivirus Solutions to Strengthen Cell and Gene Therapy Quality Control

April 29, 2025

From QIAGEN N.V.

Via Business Wire

QIAGEN Advances Cancer Genomic Profiling With New Products and Partnership Updates at AACR Annual Meeting 2025

April 22, 2025

From QIAGEN N.V.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.